{
    "clinical_study": {
        "@rank": "102607", 
        "brief_summary": {
            "textblock": "This study is a randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol\n      to target the microenvironment in resectable pancreatic cancer to determine the effect of\n      targeting the vitamin D metabolic program in the tumors of patients treated with one cycle\n      of gemcitabine/abraxane with or without paricalcitol prior to surgery for resectable\n      pancreatic cancer through an assessment of cellular and imaging markers."
        }, 
        "brief_title": "A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Patients Must Have Previously Untreated Apparently Resectable Adenocarcinoma", 
            "of the Pancreas."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have previously untreated apparently resectable adenocarcinoma of the\n             pancreas at registration.\n\n          -  Patients must be age 18 years or older\n\n          -  Standard laboratory criteria for hematologic, biochemical, and urinary indices.\n\n          -  Patients must have an ECOG performance status of 0-2.\n\n          -  Patients must be able to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who are currently pregnant, planning to become pregnant, or breast-feeding.\n\n          -  Patients who, in the opinion of the physician, would not be clinically appropriate\n             for receipt of the therapy regimen associated with participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030860", 
            "org_study_id": "UPCC 23213"
        }, 
        "intervention": {
            "description": "Dose:  25 micrograms Route: IV Regimen: 3x weekly, approximately 28 days before surgery", 
            "intervention_name": "Paricalcitol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ergocalciferols"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Peter O'Dwyer, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Peter O'Dwyer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Peter O'Dwyer, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Peter O'Dwyer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}